30 October 2025
It has been a little under a year since Dr Olivia Burn returned to the Malaghan Institute from the Icahn School of Medicine at Mount Sinai Hospital in New York. During her time overseas, she gained expertise in advanced liver cancer models and techniques, which she is now applying to research in New Zealand.
Research Officer Emma Lamb (left) with Dr Olivia Burn.
Liver cancer is a growing health challenge in New Zealand, with around 400 people diagnosed each year. Survival rates remain low and treatment options are limited, making research into new therapies especially important.
Since returning from her 12-month fellowship, Dr Burn has set up the advanced liver cancer models she used at Mount Sinai Hospital, bringing this expertise to the Malaghan Institute. Combined with the institute’s existing unique mouse strains, these models allow the team to study how liver cancer vaccines interact with the immune system and explore the mechanisms that could make future liver cancer immunotherapies more effective.
“We are now in a position to dig deeper into how vaccines stimulate the immune system against liver cancer,” says Dr Burn. “Bringing back the knowledge and techniques I gained overseas has allowed us to apply them here in New Zealand and take our research further than we could have before.”
Dr Burn is now seeking further funding to take the liver cancer project to the next stage. Her work demonstrates how international collaboration strengthens the Malaghan Institute’s ability to tackle one of New Zealand’s most challenging cancers and bring potential new therapies closer to patients.
Related articles
Breakthrough Malaghan and University of Auckland cancer research advances into new biotech venture
16 June 2026
HRC funding to improve CAR T-cell ‘fitness’ and better fight cancer
11 June 2026
What's next for CAR T-cell therapy
27 May 2026
The evolution of one of humanity's oldest immunotherapies
27 May 2026
Researchers explore 'RENTAL CAR' approach to CAR T-cell therapy
21 May 2026
Ground-breaking CAR-T clinical trial hits midway milestone
15 April 2026